BTG Pactual Asset Management US LLC Sells 2,357 Shares of Royalty Pharma plc (NASDAQ:RPRX)

BTG Pactual Asset Management US LLC decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 2.6% in the fourth quarter, HoldingsChannel reports. The fund owned 88,584 shares of the biopharmaceutical company’s stock after selling 2,357 shares during the quarter. BTG Pactual Asset Management US LLC’s holdings in Royalty Pharma were worth $2,362,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Keene & Associates Inc. grew its stake in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 370 shares during the last quarter. National Bank of Canada FI grew its position in Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 371 shares during the last quarter. Blue Trust Inc. grew its position in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares during the last quarter. Sanctuary Advisors LLC increased its stake in Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock valued at $1,068,000 after purchasing an additional 388 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Royalty Pharma by 0.5% in the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company’s stock worth $2,822,000 after buying an additional 537 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $42.50.

Royalty Pharma Stock Up 2.4 %

NASDAQ:RPRX opened at $31.95 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company’s fifty day moving average price is $32.50 and its 200-day moving average price is $29.14. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The firm has a market capitalization of $18.42 billion, a P/E ratio of 22.03, a PEG ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities research analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.